Specificity
Designing for activity in the target organ while limiting unnecessary systemic exposure.
Precise by design.Purposeful by nature.
Liver-directed RNA therapeutics. An established delivery foundation. A focused ambition to restore essential function.
Explore the approach
THE SCIENTIFIC FOUNDATION
A precise approach.
A practical purpose.
RNA medicine depends on reaching the right cells. Apterna is developing liver-directed therapeutics using an established GalNAc-siRNA foundation, with innovation focused on the biology and clinical application.
The programme is designed for selective liver activity, limited systemic exposure, and a practical subcutaneous administration pathway.
SCIENCE WITH CLINICAL PERSPECTIVE
From the operating theatre to RNA discovery.
PROFESSOR NAGY HABIB · CO-FOUNDER, CHAIR & CEO
The clinical question comes first.
A hepatobiliary surgeon and Professor at Imperial College London, Professor Habib brings direct experience of the challenges faced by patients whose liver function limits treatment. His work connects surgical innovation, RNA therapeutics and biotechnology company building.
Read his full profileDELIVERY & APPLICATION
Reach the right place.
Conceptual visualisationLEAD DEVELOPMENT FOCUS
Restoring function at the source.
REGEN001 begins with the liver. The ambition is to support functional recovery in patients whose liver reserve prevents potentially curative surgery.
- Organ-directed activity
- Subcutaneous administration
- A focused clinical entry point
DESIGN PRINCIPLES
Precision is a discipline.
Safety
Investigating biodistribution, tolerability, and safety as part of the development process.
Scalability
Considering synthetic chemistry, manufacturing, and practical clinical use from the outset.
Stability and adaptability
RNA constructs are designed with persistence and developability in mind. Broader delivery capabilities may support different RNA formats as programmes and partnerships develop.
Evidence before expansion
Progression is guided by mechanistic rationale, preclinical validation, and regulatory preparation. Later-stage plans remain dependent on the evidence generated.
THE TRANSLATIONAL PATH
Each step earns the next.
PLANNED · 2026
Lead selection
Optimisation and in vitro proof of concept to test the intended biological effect.
Company development plan. Timelines are prospective and depend on funding, study outcomes, and regulatory review.
CONTINUE EXPLORING
Explore what comes next.
A CLEARER UNDERSTANDING
Questions about our work.
What type of RNA therapeutics is Apterna developing?
Apterna is developing liver-directed RNA therapeutics using a GalNAc-siRNA foundation. Its lead programme, REGEN001, is focused on liver functional restoration and remains in preclinical development.
What is the role of GalNAc in Apterna’s approach?
GalNAc is the liver-directed delivery foundation used in Apterna’s programme. Apterna’s research focuses on the biological application and evidence needed to evaluate its intended effect on liver function.
Has Apterna demonstrated clinical efficacy?
REGEN001 is a preclinical, investigational programme. The website describes development aims and planned research; it does not establish clinical efficacy or an approved treatment.